transcatheter aortic valve replacement (TAVR), heart bypass surgery, heart failure, abdominal aortic aneurysm repair and heart attack. For 34 consecutive years, UCLA Health hospitals have earned a ...

The company estimates that more than 42,000 valve-in-valve procedures will be performed annually in the U.S. by 2035, accounting for about 15% of all TAVR surgeries. Pi-Cardia said it also plans ...

New York, New York-- (Newsfile Corp. - October 20, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE ...

The Structural Heart team at the Chinese General Hospital and Medical Center (CGHMC) Heart Institute, under the leadership of ...

With this expansion came a better understanding of associated complications. Spinal cord ischemia, perhaps the most dreaded complication of aortic surgery short of death, led to an understanding of ...

Abbott Laboratories ABT is slated to report its third-quarter 2024 results on Oct. 16, before the opening bell. The company ...

The early presentation of the Transcatheter Aortic Valve Replacement (TAVR) data at the TCT conference, instead of the American College of Cardiology (ACC) next year, suggests strong confidence in ...

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, provides products and technologies for structural ...

Innovations such as the RESILLIA technology enhance the performance of the company’s TAVR (Transcatheter Aortic Valve Replacement) business. Additionally, progress within the TMTT (Transcatheter ...

Edwards describes itself as an “international company that researches, develops, provides products and technologies for heart valve repair and replacement ... of Edwards’ core product, Transcatheter ...

The TAVR segment has been a cornerstone of Edwards Lifesciences ... Innovative technologies: Edwards Lifesciences' TMTT portfolio, including products like Pascal for mitral repair, is gaining traction ...